Pimasertib (AS-703026) Chemical Structure
AS703026 is a novel, selective, orally bioavailable MEK1/2 inhibitor, in human multiple myeloma (MM). AS703026 inhibited growth and survival of MM cells (cell IC50 ranging from 0.005 to 2 μM) and cytokine-induced osteoclast differentiation more potently (9- to 10-fold) than AZD6244. Inhibition of proliferation induced by AS703026 was mediated by G0-G1 cell cycle arrest and was accompanied by reduction of MAF oncogene expression.
Importantly, AS703026 sensitized MM cells to a broad spectrum of conventional (dexamethasone, melphalan), novel or emerging (lenalidomide, perifosine, bortezomib, rapamycin) anti-MM therapies. 
 Br J Haematol. 2010 May;149(4):537-49.
|Molecular Weight (WM):||431.20|
A collection of 1159 inhibitors
A collection of 271 kinase inhibitors
A collection of 853 FDA approved drugs
A collection of 144 natural products
A collection of 1650 bioactive compounds
A collection of 118 tyrosine kinase inhibitors
;Dr. Zhang of Tianjin Medical University Pimasertib (AS-703026) purchased from Selleck
Keywords:buy Pimasertib (AS-703026) | Pimasertib (AS-703026) supplier | purchase Pimasertib (AS-703026) | Pimasertib (AS-703026) cost | Pimasertib (AS-703026) manufacturer | order Pimasertib (AS-703026) | Pimasertib (AS-703026) distributor